- Home
- NAAS vs NNVC Comparison
NAAS vs NNVC Comparison
Compare NAAS & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | NNVC |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 37.9M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NAAS | NNVC |
|---|---|---|
| Price | $3.35 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 321.1K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $0.85 |
| 52 Week High | $4.54 | $2.23 |
Technical Indicators
Market Signals| Indicator | NAAS | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 39.11 |
| Support Level | $3.26 | $1.24 |
| Resistance Level | $3.47 | $1.47 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 50.00 | 13.89 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.